Mutation-resistant drugs against pandemic influenza are moving forward slowly. Here are quotes from a recent press release:

NanoViricides, Inc., reported today [22 Jan 2008] that they are on course with the development of nanoviricides™ drug candidates against highly pathogenic avian influenzas (HPAI) including H5N1 bird flu, and common influenza. “We are now ready to begin animal studies on H5N1 at a renowned federal agency," said Dr. Eugene Seymour, MD, MPH, CEO of the Company.

[...]

There are currently no effective treatments against H5N1, or the class of pandemic threatening viruses called HPAI. “The broad-spectrum FluCide™, and the HPAI-specific FluCide-HP™, are designed using the virus’s host cell-binding features that do not change even when the virus mutates,” says Anil R. Diwan, Ph.D., President of the Company. This feature would potentially make these two drugs the best current treatment options for development, says the Company. Vaccines and Antibodies could lose effectiveness due to mutations. H5N1 resistance to Tamiflu® is well known, and resistance against other existing same-class (neuraminidase inhibitor) drugs such as peramivir and possibly Relenza® could occur due to virus mutations.

http://biz.yahoo.com/bw/080122/20080122005644.html